Inhibitor combination and its application in the preparation of drugs for treating MYC-overexpressing cancer
Through the combination of CTPS and ATR inhibitors, the lack of drug targeting MYC protein in the existing technology has been solved, and the selective killing of MYC-high-expressing tumor cells is achieved, reducing damage to normal cells, and bypassing the target problem of MYC protein. .
Patent Information
- Application Number
- CN202111234096.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2021-10-22
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2041-10-22
AI Technical Summary
The prior art lacks clinical drugs targeting MYC proteins and methods for selective killing of MYC-highly expressed tumor cells, and MYC proteins are considered to be unmedical-available targets.
Provided is a pharmaceutical composition, including CTPS inhibitors and ATR inhibitors, such as the combination of 3-deazauridine with BAY-1895344, VE-822 and AZD6738, to selectively induce DNA replication by inhibiting CTPS1 and ATR. Activation and apoptosis reduce toxic side effects on normal cells.
This composition can effectively selectively kill MYC-highly expressed tumor cells, improve the killing effect on MYC-highly expressed cells, and reduce the toxic side effects on normal cells, and bypass the target problem of MYC protein itself.
Smart Images

Figure CN115998885B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine, and in particular to an application of an inhibitor combination in preparing a drug for treating cancer, in particular to an application of 3-deazauridine and one or more of BAY-1895344, VE-822 and AZD6738 in preparing a drug for treating MYC-overexpressing cancer. Background Art
[0002] Uncontrolled MYC protein expression is involved in the occurrence and development of 70-80% of human cancers. Its uncontrolled expression can be attributed to gene translocation, increased gene copy number, upregulation of mRNA transcription, and blocked protein degradation. Studies based on mouse tumor models have shown that silencing MYC gene expression can significantly inhibit or even regress tumors. For example, in the Tet-off MYC liver cancer model and osteosarcoma model, silencing MYC gene expression can induce tumor regression and differentiation; in the APC deficiency-induced intestinal tumor model, small intestine-specific knockout of MYC significantly inhibited intestinal tumor occurrence. These excellent mouse experimental results have greatly stimulated people's enthusiasm for treating tumors by targeting MYC. However, due to the lack of obvious small molecule drug binding pockets on the surface of the MYC protein and the severe toxic side effects caused by long-term inhibition of MYC, MYC has long been considered an "undruggable target".
[0003] Metabolic reprogramming is an important feature of tumor cells. MYC maintains the various substances required for rapid proliferation, growth and survival of tumor cells by activating multiple anabolic processes simultaneously, such as nucleotide synthesis, protein synthesis and lipid synthesis. These processes must be tightly regulated to maintain metabolic balance. An important function of MYC is to activate rRNA synthesis by co-regulating RNA polymerases I, II and III, thereby meeting the demand for ribosomes for the synthesis of various proteins required for the rapid proliferation of MYC high-expressing cells. Ribosomal RNA (rRNA) accounts for more than 50% of the total ribosomal biomass, and more than 85% of RNA in cells exists in the form of rRNA. Therefore, rRNA is the most important storage site for nucleotides in cells, and the increase in rRNA synthesis must be accompanied by a significant increase in the cell's demand for nucleotides. In order to meet the large demand for nucleotides, MYC activates the expression of multiple enzymes involved in nucleotide metabolism, while activating glycolysis and the pentose phosphate pathway to provide the necessary precursors for the synthesis of purine and pyrimidine nucleotides. The synthesized nucleotides will be mainly used for rRNA synthesis to meet the large demand for protein for the growth of MYC high-expressing cells, and will be converted into deoxyribonucleotides for DNA replication. Therefore, limiting the supply of intracellular purine or pyrimidine nucleotides while maintaining MYC activity, thereby breaking the nucleotide supply and demand balance established by MYC through metabolic reprogramming, will likely selectively inhibit or even kill MYC high-expressing cells. For example, in small cell lung cancer with high MYC expression, specific inhibition of IMPDH, the rate-limiting enzyme for guanine nucleotide synthesis, can significantly inhibit tumor growth. By inhibiting PRPS2 activity to limit the supply of PRPP, a common precursor for the synthesis of purine and pyrimidine nucleotides, MYC high-expressing cells can be specifically killed.
[0004] CTP is the lowest content of the four ribonucleotides (UTP, ATP, GTP and CTP) in the cell, which makes CTP the rate-limiting molecule for nucleic acid (DNA and RNA) synthesis and other CTP-dependent biological processes. CTP can be synthesized through the denovo synthesis pathway and the salvage pathway, of which the de novo synthesis pathway provides approximately 70% of the CTP supply in the cell. The rate-limiting step and the last step of CTP de novo synthesis is the conversion of UTP into CTP by CTP synthetase (CTPS). CTPS protein expression and enzyme activity are significantly increased in a variety of tumor tissues, including colorectal cancer. Human CTPS has two subtypes: CTPS1 and CTPS2, which have similar enzyme catalytic activities. Current studies have not found significant functional differences between the two.
[0005] Currently, there is no clinical drug targeting MYC protein, and there is an urgent need for a method that can selectively kill tumor cells with high expression of MYC protein. Summary of the invention
[0006] In order to solve the defects of the prior art that there is a lack of clinical drugs targeting MYC protein and methods for selectively killing tumor cells with high expression of MYC protein, the present invention provides an inhibitor combination and its use in the preparation of a drug for treating cancer with high MYC expression. Specifically, the present invention provides an inhibitor combination in the form of a pharmaceutical composition or a kit and its use in the preparation of a drug for treating cancer, especially a combination of a CTPS inhibitor and an ATR inhibitor such as 3-deazauridine and one or more of BAY-1895344VE-822 and AZD6738 and its use in the preparation of a drug for treating cancer with high MYC expression.
[0007] MYC satisfies the large demand for protein by the rapid proliferation of malignant tumor cells by activating ribosomal RNA (rRNA) synthesis, and rRNA synthesis leads to a sharp increase in nucleotide demand. CTP is the lowest content of the four ribonucleotides (UTP, ATP, GTP and CTP) in the cell, and is the rate-limiting molecule of related biological processes. CTP is mainly synthesized by the de novo synthesis pathway mediated by CTPS. The present invention also found that inhibition of CTPS can selectively induce DNA replication stress in MYC high-expressing cells, and DNA replication stress protects genome stability by activating ataxia telangiectasia and Rad3-related protein (ATR) and its downstream Chk1-mediated S phase checkpoint. Combined inhibition of CTPS and ATR selectively induces DNA damage and apoptosis in MYC high-expressing tumor cells. The present invention first found that the combination of CTPS inhibitors and ATR inhibitors has a better effect of inhibiting MYC high-expressing cells.
[0008] In order to solve the above technical problems, one of the technical solutions of the present invention is: to provide a pharmaceutical composition, characterized in that it comprises a CTPS inhibitor and an ATR inhibitor.
[0009] Preferably, the CTPS inhibitor is 3-deazauridine (DAU), which is shown in the following structural formula:
[0010]
[0011] There are two subtypes of human CTPS: CTPS1 and CTPS2. MYC increases the intracellular CTP concentration by specifically inducing CTPS1 expression; interfering with CTPS1 alone, but not CTPS2, can selectively induce DNA replication stress in MYC-high-expressing cells, and selectively kill MYC-high-expressing tumor cells when combined with ATR inhibitors. Since normal cells can provide CTP for normal cell growth and proliferation through CTPS2 and the salvage synthesis pathway. Therefore, preferably, the combined inhibition of CTPS1 and ATR can further improve the selectivity of killing MYC-high-expressing tumor cells and reduce the toxic side effects on normal cells. Therefore, preferably, the CTPS inhibitor is a CTPS1 inhibitor, such as compound A shown in the following formula:
[0012]
[0013] Or, preferably, the ATR inhibitor is BAY-1895344, VE-822 and / or AZD6738 as shown below.
[0014]
[0015] Inhibition of CTPS1 can selectively induce DNA damage in MYC high-expressing cells. Cells participate in DNA damage repair by activating CHK1 / 2, ATM, PARP1 / 2, WEE1, and DNA-PK pathways. Inhibition of these key signaling pathways involved in DNA damage repair while inhibiting CTPS1-induced DNA damage will lead to severe DNA damage and cell apoptosis. Therefore, in some preferred embodiments, the pharmaceutical composition also includes one or more inhibitors targeting CHK1 / 2, ATM, PARP1 / 2, WEE1, or DNA-PK.
[0016] Preferably, the pharmaceutical composition further comprises one or more other CTPS inhibitors except 3-deazauridine, other ATR inhibitors except BAY-1895344, VE-822 and AZD6738.
[0017] In order to solve the above technical problems, the second technical solution of the present invention is: to provide a set of medicine kits, the set of medicine kits comprising medicine kit A and medicine kit B, wherein the medicine kit A comprises a CTPS inhibitor, and the medicine kit B comprises an ATR inhibitor.
[0018] Preferably, the CTPS inhibitor is a CTPS1 inhibitor, and the ATR inhibitor is one or more of BAY-1895344, VE-822 and AZD6738.
[0019] More preferably, the CTPS inhibitor is 3-deazauridine.
[0020] Even more preferably, the drug kit A is administered before the drug kit B, the drug kit A is administered after the drug kit B, or the drug kit A and drug kit B are administered simultaneously.
[0021] In some preferred embodiments, the kit further comprises kit C; the kit C comprises one or more inhibitors targeting CHK1 / 2, ATM, PARP1 / 2, WEE1, DNA-PK, and / or the kit C comprises one or more CTPS inhibitors other than 3-deazauridine, and other ATR inhibitors other than BAY-1895344, VE-822 and AZD6738.
[0022] Preferably, the order of administration of the medicine box A, medicine box B and medicine box C is: medicine box A, medicine box B, medicine box C; or medicine box A, medicine box C, medicine box B; or medicine box B, medicine box A, medicine box C; or medicine box B, medicine box C, medicine box A; or medicine box C, medicine box A, medicine box B; or medicine box C, medicine box B, medicine box A; or simultaneous administration.
[0023] In order to solve the above technical problems, the third technical solution of the present invention is to provide a method for selectively killing tumor cells with high expression of MYC for non-therapeutic purposes, wherein the method is to contact the pharmaceutical composition described in any one of the technical solutions of the present invention or the set of medicine kits described in any one of the technical solutions of the present invention with the tumor cells. The non-therapeutic method can, for example, kill tumor cells with high expression of MYC in the laboratory to study the prepared cell model, or to study the synergistic effect between drugs, so as to develop more compounds or combination drugs targeting tumor cells with high expression of MYC.
[0024] Preferably, the tumor cells are hematological tumors or solid tumors.
[0025] More preferably, the blood tumor includes multiple myeloma or lymphoma; the solid tumor is breast cancer, liver cancer, melanoma, papilloma, osteosarcoma, neuroblastoma, pancreatic cancer, prostate cancer, kidney cancer or intestinal cancer such as colorectal cancer or colon cancer.
[0026] In order to solve the above technical problems, the fourth technical solution of the present invention is: to provide a pharmaceutical composition as described in any one of the technical solutions of the present invention and a kit as described in any one of the technical solutions of the present invention for use in the preparation of a drug for treating MYC-overexpressing cancer.
[0027] In some preferred embodiments, the MYC-high expressing cancer is a hematological tumor or a solid tumor.
[0028] Preferably, the blood tumor includes multiple myeloma or lymphoma; the solid tumor is breast cancer, liver cancer, melanoma, papilloma, osteosarcoma, neuroblastoma, pancreatic cancer, prostate cancer, kidney cancer or intestinal cancer such as colorectal cancer or colon cancer.
[0029] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present invention.
[0030] The reagents and raw materials used in the present invention are commercially available.
[0031] The positive and progressive effects of the present invention are:
[0032] Due to the undruggability of MYC protein, it is extremely difficult to develop anti-tumor drugs by directly targeting MYC. The present invention bypasses MYC itself, selectively induces replication stress in MYC high-expressing cells by inhibiting CTPS, and selectively kills MYC high-expressing tumor cells when combined with ATR activity inhibition. In the preferred technical scheme, selective interference with CTPS1 activity combined with ATR inhibitors such as BAY-1895344, VE-822 or AZD6738 can further improve the selectivity for MYC high-expressing cells and reduce the toxic side effects on normal cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 The results showed that the compound selectively inhibited the cell viability of cells with high MYC expression.
[0034] Figure 2 This is the effect of DAU on the cell cycle of cells with high MYC expression.
[0035] Figure 3 DAU induced the phosphorylation modification of Chk-1 Ser345 and ATR Thr1989 in MYC high-expressing cells in a concentration-dependent manner.
[0036] Figure 4 Combined inhibition of CTPS and ATR selectively induced DNA damage in MYC high-expressing cells ARPE-19-MYC.
[0037] Figure 5 Combined inhibition of CTPS and ATR selectively induced DNA damage in MYC high-expressing cells RKO, HCT116 and SW480.
[0038] Figure 6 Combined inhibition of CtpS and ATR induced DNA damage that was dependent on MYC activity.
[0039] Figure 7 To jointly inhibit CTPS and ATR to induce apoptosis in cells with high MYC expression.
[0040] Figure 8 Combined inhibition of CtpS and ATR induced apoptosis that depended on MYC activity.
[0041] Fig. 9 Combined inhibition of CTPS and ATR inhibits tumor growth in vivo.
[0042] Fig.10 The combined inhibition of CTPS and ATR induced apoptosis in MYC-overexpressing cells was not affected by the status of P53 and HRAS.
[0043] Fig.11 Knockout of CTPS1 combined with ATR inhibitor induced apoptosis of cells with high MYC expression.
[0044] Fig.12 Knockdown of CTPS1 combined with ATR inhibitor induced apoptosis of cells with high MYC expression.
[0045] Fig.13 The methods of overexpressing and knocking down MYC were used to investigate the correlation between MYC and CTPS1 and CTPS2 mRNA expressions.
[0046] Fig.14 To investigate the effects of inhibiting CTPS1 and CTPS2 alone or in combination on the viability of MYC-overexpressing tumor cells.
[0047] Fig.15 This is a technical principle diagram of the present invention. DETAILED DESCRIPTION
[0048] The present invention is further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods in the following examples without specifying specific conditions are carried out according to conventional methods and conditions, or selected according to the product specifications.
[0049] Example 1 Inhibition of CTPS selectively inhibits cell viability of MYC-overexpressing cells
[0050] In order to study the role of CTPS in MYC-driven tumor cell growth, we first constructed a stable cell line ARPE-19-Tet-On-MYC-CMV-Puro that can inducibly express MYC in normal human retinal epithelial cells ARPE-19. Hereinafter, the stable cell line will be referred to as ARPE-19-MYC. Therefore, the cells to which DOX was added to activate MYC expression were named ARPE-19-MYC (DOX+), and the cells without DOX stimulation were named ARPE-19-MYC (DOX-). Then, the two ARPE-19-MYC models were verified using two previously reported compounds Purvalanol A and VX-680 that can selectively induce apoptosis of MYC-overexpressing cells. These two compounds target and inhibit CDK1 and aurora-B kinase, respectively. The results showed that both compounds can selectively inhibit the cell viability of ARPE-19-MYC (DOX+) ( Figure 1 A and B) and cell death ( Figure 1 C). ARPE-19-MYC(DOX+) and ARPE-19-MYC(DOX-) cells were then treated with the CTPS inhibitor DAU to investigate the effect of CTPS inhibition on cell viability and its correlation with MYC expression. The results showed that DAU had a stronger inhibitory effect on ARPE-19-MYC(DOX+) cell viability than ARPE-19-MYC(DOX-). Figure 1 In addition, shRNA was used to knock down MYC expression in various MYC-highly expressed tumor cells RKO, HCT116 and SW480, and then the sensitivity of cells expressing control and MYCshRNA to DAU was compared. The results showed that knocking down MYC significantly weakened the sensitivity of DAU to RKO ( Figure 1 F and G), SW480( Figure 1 H and I) and HCT116 ( Figure 1 J and K) Inhibition of cell viability. These experimental results indicate that inhibition of Ctps can selectively inhibit the cell viability of cells with high MYC expression.
[0051] Example 2 DAU selectively induces replication stress in cells with high MYC expression
[0052] In order to reveal the reason why inhibition of CTPS selectively inhibits the viability of MYC-overexpressing cells, the effect of DAU on the cell cycle was examined. The present invention found that DAU could significantly arrest ARPE-19-MYC (DOX+) cells in the S phase, while having only a weak effect on ARPE-19-MYC (DOX-) cells ( Figure 2In addition, the proportion of S phase cells in RKO, HCT116 and SW480 cells also increased significantly after DAU treatment, and the proportion of G1 and G2 phase cells decreased significantly ( Figure 2 C, D and E), while in MYC knockdown RKO, HCT116 and SW480 cells, DAU had no significant effect on the cell cycle ( Figure 2 F, G, and H). The experimental results show that inhibition of CTPS selectively prevents the completion of S phase DNA replication in MYC-overexpressing cells.
[0053] Based on the above data that DAU prevents the completion of S phase DNA replication in MYC-overexpressing cells, it is speculated that inhibition of CTPS may selectively cause DNA replication stress in MYC-overexpressing cells. The present invention evaluates DNA replication stress by detecting the phosphorylation modification of Chk-1 Ser34 and ATR Thr1989. The experimental results showed that DAU induced phosphorylation modification of Chk-1 Ser345 and ATR Thr1989 in ARPE-19-MYC (DOX+) cells in a concentration-dependent manner, while there was no significant change in the phosphorylation modification of Chk-1 Ser345 and ATR Thr1989 in ARPE-19-MYC (DOX-) cells before and after DAU treatment ( Figure 3 In addition, RKO, HCT116, SW480 and Raji cells with high MYC expression also showed obvious phosphorylation modification of Chk-1 Ser345 and ATR Thr1989 after DAU treatment ( Figure 3 More importantly, after knocking down MYC expression, DAU-induced Chk-1Ser345 and ATR Thr1989 phosphorylation modifications were significantly weakened ( Figure 3 C and D). These results suggest that inhibition of CtpS induces DNA replication stress in MYC-overexpressing cells in a MYC-dependent manner.
[0054] Example 3 Combined inhibition of CTPS and ATR induces DNA damage in a MYC-dependent manner
[0055] DNA replication stress protects genome stability by activating the ATR-Chk1 signaling pathway. Continuous and unrelieved DNA replication stress will lead to DNA damage and cell apoptosis. Next, we investigated whether the combined inhibition of CTPS and ATR could selectively induce DNA damage in MYC high-expressing cells. DNA damage was evaluated by detecting the phosphorylation modification of H2AX Ser139. Immunofluorescence staining results showed that after 16 hours of combined treatment with DAU and the ATR inhibitor BAY-1895344, more than 60% of ARPE-19-MYC (DOX+) cells were positive for H2AX Ser139 phosphorylation modification, while in ARPE-19-MYC (DOX-) cells, less than 10% of cells were positive for H2AX Ser139 phosphorylation modification ( Figure 4 In addition, Western blot (WB) results also showed that the combination of DAU and BAY-1895344 or two other ATR inhibitors, AZD6738 and VE-822, significantly increased H2AX Ser139 phosphorylation modification in ARPE-19-MYC cells, but had no significant effect on ARPE-19-Puro cells ( Figure 4 In addition, the comet assay results also showed that the combination of DAU and the ATR inhibitor BAY-1895344 significantly increased the DNA content of the comet tail of ARPE-19-MYC (DOX+) cells, but had no significant effect on ARPE-19-MYC (DOX-) cells ( Figure 4 In addition, RKO, HCT116 and SW480 cells also showed significant increase in H2AX Ser139 phosphorylation modification after combined treatment with DAU and ATR inhibitors ( Figure 5 The comet assay results also showed that the combination of DAU and the ATR inhibitor BAY-1895344 significantly increased the DNA content of the comet tails of RKO, HCT116, and SW480 cells ( Figure 5 D and E). After shRNA knockdown of MYC expression, the phosphorylation modification of H2AX Ser139 induced by the combination of DAU and ATR inhibitors was significantly weakened ( Figure 6 Comet assay results also showed that knocking down MYC significantly reversed the increase in DNA content in the comet tail induced by the combination of DAU and ATR inhibitors ( Figure 6 C and D).
[0056] Example 4 Combined inhibition of CTPS and ATR induces apoptosis in a MYC-dependent manner
[0057] Next, the effect of combined inhibition of CTPS and ATR on cell apoptosis was investigated by Annexin V / PI staining. The results showed that ARPE-19-MYC (DOX+) and ARPE-19-MYC (DOX-) could not induce obvious cell apoptosis when treated with DAU or BAY-1895344 alone. However, after combined treatment with DAU and BAY-1895344, about 60% of ARPE-19-MYC (DOX+) cells underwent obvious apoptosis, while ARPE-19-MYC (DOX-) cells showed no significant changes ( Figure 7 A). Two other ATR inhibitors, AZD6738 and VE-822, can also significantly induce apoptosis in ARPE-19-MYC (DOX+) cells after combined treatment with DAU ( Figure 7 B), and apoptosis induced by the combination of DAU and ATR inhibitors could be reversed by the pan-caspase inhibitor Q-VD ( Figure 7 C), indicating that caspase activation is the main reason for the induction of apoptosis by the combined DAU and ATR inhibitors. Tumor cells with uncontrolled MYC expression may have adapted to the high expression of MYC due to various mutations, and are therefore insensitive to the combined inhibition of CTPS and ATR-induced apoptosis. Next, the apoptosis-inducing effect of the combined inhibition of CTPS and ATR was tested in tumor cells with uncontrolled MYC expression. In HCT116, RKO, SW480, and Raji cells, DAU or BAY-1895344 alone could not induce obvious apoptosis, however, the combined treatment of DAU and BAY-1895344 for 48 hours significantly increased the proportion of apoptotic cells ( Figure 7 In addition, the proportion of apoptotic cells in HCT116 and RKO cells expressing ATR shRNA was significantly increased after DAU treatment compared with cells expressing control shRNA ( Figure 8 More importantly, after knocking down MYC, the apoptosis induced by the combination of DAU and BAY-1895344 was significantly reversed ( Figure 8 C, D, and E). These results suggest that combined inhibition of CTPS and ATR can selectively induce DNA damage and apoptosis in MYC-overexpressing cells.
[0058] Example 5 Combination of DAU and BAY-1895344 to inhibit tumor growth in vivo
[0059] In order to detect the in vivo therapeutic effect of the combination of DAU and BAY-1895344, 3D cell culture models of RKO, HCT116 and ARPE-19-MYC (DOX+) were first established. It was found that although DAU and BAY-1895344 alone could reduce the volume of tumor spheroids to a certain extent, when the two were combined, the volume of tumor spheroids was only about 5%-10% of that of the control group ( Fig. 9 A). Next, a nude mouse xenograft tumor model was constructed using HCT116 cells, and then DAU and BAY-1895344 were given alone or in combination, and the tumor growth curve was recorded ( Fig. 9 After the experiment, the tumor tissue was separated and weighed ( Fig. 9 C and D), the results showed that the tumor suppression effect of the combination of DAU and BAY-1895344 was significantly better than that of either drug alone.
[0060] Since MYC-overexpressing cells are often accompanied by RAS mutations and P53 loss, which synergistically promote tumor cell survival and proliferation, we next investigated whether overexpression of constitutively activated HRAS (HRAS G12V ) or whether cells with knockdown of P53 are still sensitive to the combined treatment of DAU and BAY-1895344. G12V Or ARPE-19-MYC (DOX+) cells with P53 knockdown still underwent significant apoptosis after combined treatment with DAU and BAY-1895344 ( Fig.10 A, B and C).
[0061] Example 6 Combined inhibition of CTPS1, but not CTPS2, and ATR induces apoptosis in MYC-overexpressing cells
[0062] CTPS activity is catalyzed by two isoforms, CTPS1 and CTPS2. In order to clarify the role of CTPS1 and CTPS2 in MYC-driven tumor cell growth, CRISPR technology was used to construct cell lines in RKO cells in which CTPS1 and CTPS2 were knocked out alone or both. When treated with the ATR inhibitor BAY-1895344, the apoptosis rate of cells in which CTPS1 was knocked out alone and CTPS1 and CTPS2 were knocked out simultaneously increased significantly, while there was no significant effect on cells in which CTPS2 was knocked out ( Fig.11 A). WB results showed that knocking out CTPS1 alone could lead to severe DNA replication stress, and the extent was not significantly different from that of knocking out CTPS1 and CTPS2 simultaneously, while knocking out CTPS2 had no significant effect on DNA replication stress ( Fig.11In order to exclude the off-target effect of CRISPR, Flag-CTPS1 and Flag-CTPS2 were overexpressed in CTPS1 knockout cells. The results showed that overexpression of CTPS1 or CTPS2 could completely reverse BAY-1895344-induced apoptosis ( Fig.11 In addition, the same phenomenon was observed when shRNA was used to knock down CTPS1 and CTPS2 in HCT116 and RKO cells separately or simultaneously. When treated with the ATR inhibitor BAY-1895344, cells with CTPS1 knockdown alone or with both CTPS1 and CTPS2 knockdown both underwent significant apoptosis to a similar extent, while knocking down CTPS2 had no significant effect ( Fig.12 At the same time, knocking down CTPS1 alone can lead to a similar degree of DNA replication stress as knocking down both CTPS1 and CTPS2, while knocking down CTPS2 has no significant effect on DNA replication stress ( Fig.12 C and D). These results suggest that CTPS1 plays a critical role in MYC-driven tumors.
[0063] In order to reveal the molecular mechanism of the key role of CTPS1 in MYC-driven tumors, the correlation between MYC and the mRNA expressions of CTPS1 and CTPS2 was investigated by overexpression and knockdown of MYC. RT-PCR results showed that the mRNA level of CTPS1 increased or decreased significantly when MYC was overexpressed or knocked down, while the mRNA expression of CTPS2 changed only slightly under the same conditions ( Fig.13 WB results also showed that when MYC was overexpressed or knocked down, the protein level of CTPS1 increased or decreased significantly, while the protein level of CTPS2 changed only slightly under the same conditions ( Fig.13 D, E, and F). These results suggest that MYC may provide CTP for rapid cell proliferation by selectively inducing CTPS1 but not CTPS2 gene expression.
[0064] Example 7 Inhibition of CTPS1 selectively inhibits cell viability of MYC-overexpressing cells
[0065] Next, we investigated the effect of genetic intervention on CTPS1 expression on the viability of MYC-overexpressing tumor cells. The results of the CCK8 experiment showed that knocking out CTPS1 could significantly inhibit the viability of RKO cells, and its degree was comparable to the effect of knocking out CTPS1 and CTPS2 at the same time on cell viability, while knocking out CTPS2 alone had no significant effect on cell viability ( Fig.14In addition, the same phenomenon was observed when shRNA was used to knock down CTPS1 and CTPS2 separately and simultaneously in HCT116 and RKO cells, that is, knocking down CTPS1 alone and knocking down CTPS1 and CTPS2 simultaneously could effectively inhibit cell viability, while knocking down CTPS2 had no obvious effect ( Fig.14 In cells expressing Myc shRNA, knockdown of CTPS1 had no significant effect on cell viability ( Fig.14 D), indicating that inhibition of CTPS1 selectively suppresses the cell viability of MYC-overexpressing tumor cells.
[0066] Thus, the technical principle diagram of the present invention is constructed ( Fig.15 ), among which MYC upregulates CTPS1 through metabolic reprogramming to provide CTP for ribosome synthesis and DNA replication for the rapid proliferation of tumor cells, inhibits CTPS1 to selectively induce DNA replication stress in MYC high-expressing tumor cells, and jointly inhibits CTPS1 and ATR to selectively induce DNA damage and apoptosis in MYC high-expressing tumor cells.
Claims
1. A pharmaceutical composition, It is characterized in that The invention comprises a CTPS inhibitor and an ATR inhibitor, wherein the CTPS inhibitor is 3-deazauridine and the ATR inhibitor is BAY-1895344.
2. The pharmaceutical composition according to claim 1, It is characterized in that The pharmaceutical composition also includes one or more inhibitors targeting CHK1 / 2, ATM, PARP1 / 2, WEE1, and DNA-PK.
3. The pharmaceutical composition according to claim 2, It is characterized in that The pharmaceutical composition may further include one or more other CTPS inhibitors other than 3-deazauridine, and other ATR inhibitors other than BAY-1895344.
4. A medicine kit, comprising a medicine kit A and a medicine kit B, It is characterized in that The drug kit A comprises a CTPS inhibitor, and the drug kit B comprises an ATR inhibitor; Wherein, the ATR inhibitor is BAY-1895344; the CTPS inhibitor is 3-deazauridine.
5. The kit according to claim 4, It is characterized in that The drug kit A is administered before the drug kit B, the drug kit A is administered after the drug kit B, or the drug kit A and drug kit B are administered simultaneously.
6. The kit according to claim 5, It is characterized in that The drug kit also includes a drug kit C; the drug kit C includes one or more inhibitors targeting CHK1 / 2, ATM, PARP1 / 2, WEE1, DNA-PK, and / or the drug kit C includes one or more CTPS inhibitors other than 3-deazauridine, and other ATR inhibitors other than BAY-1895344.
7. The kit of claim 6, It is characterized in that The order of administration of the medicine box A, medicine box B and medicine box C is: medicine box A, medicine box B, medicine box C; or medicine box A, medicine box C, medicine box B; or medicine box B, medicine box A, medicine box C; or medicine box B, medicine box C, medicine box A; or medicine box C, medicine box A, medicine box B; or medicine box C, medicine box B, medicine box A; or simultaneous administration.
8. Use of the pharmaceutical composition according to any one of claims 1 to 3 or the drug kit according to any one of claims 4 to 7 in the preparation of a drug for treating lymphoma or colon cancer.
